international oncolytic virus conference

# IOVC 2022

## 14th International Oncolytic Virotherapy Conference

## Program

Date | October 23 - 26, 2022

Venue | Karuizawa Prince Hotel West
Karuizawa, Nagano, Japan

President | Tomoki Todo, M.D., Ph.D.
Professor
Division of Innovative Cancer Therapy, and
Department of Surgical Neuro-Oncology
The Institute of Medical Science
The University of Tokyo

http://iovc2022.umin.jp/

KARUIZAWA, JAPAN

## Thank you to our partners for their support:

### International Sponsors

### Diamond Level

KALIVIR IMMUNOTHERAPEUTICS

### Platinum Level

Replimune

### Gold Level

TURNSTONE BIOLOGICS

### Silver Level

GENEMEDICINE

### Bronze Level

CG ONCOLOGY

# Contents

## Welcome

# Dear Colleagues and Friends,

On behalf of the international organizing committee and the local organizing committee, it is my honor and great pleasure to welcome you to the 14th International Oncolytic Virotherapy Conference in Karuizawa, Nagano, Japan. This is the first time this conference is held outside North America and Europe. Due to the COVID-19 pandemic, we postponed this Karuizawa meeting twice, and although we hold it this year as a hybrid meeting, I am happy to announce that the majority of participants manage to attend this meeting in person. Whether participating in person or virtual, I sincerely thank you for attending this meeting in these difficult circumstances.

After a long period of basic and translational research, multiple oncolytic virus therapy products are now in the market, including talimogene laherparepvec approved for malignant melanoma in US and Europe and teserpaturev approved for malignant glioma in Japan. Many other oncolytic virus products are to follow. Currently, oncolytic virus therapy is one of the most rapidly progressing and the most competitive field of drug development.

The purpose of this conference is to bring together experts in this field from around the world to discuss cutting-edge technologies and regulatory science, and, furthermore, to expand and deepen the friendship among this society. This conference, which began in 1997 with colleagues working on early development of oncolytic viruses, has developed into the oldest and the most authoritative international conference on oncolytic virus therapy. We received over 160 abstracts from all over the world, reflecting the enthusiasm of the researchers and rapid progress of this field. I hope the gathering and information exchange at this meeting would further facilitate the development of oncolytic virus therapy in the world.

For those who are here in person at Karuizawa, please also enjoy the brilliantly colored autumn leaves, relaxing hot springs, delicious food and Japanese tradition and culture.

**Tomoki Todo, M.D., Ph.D.**
Conference President

# Committees

## International Organizing Committee

*In alphabetical order, by last name

| | |
|---|---|
| John Bell | (Ottawa Hospital Research Institute) |
| Brian R. Champion | (PsiOxus Therapeutics) |
| E. Antonio Chiocca | (Brigham and Women's Hospital/Harvard) |
| Robert Coffin | (Replimune) |
| Kerry Fisher | (University of Oxford) |
| Evanthia Galanis | (Mayo Clinic) |
| Noriyuki Kasahara | (University of California San Francisco) |
| Martine Lamfers | (Erasmus MC) |
| Brian Lichty | (McMaster University) |
| Grant McFadden | (Arizona State University) |
| Alan Melcher | (University of Leeds) |
| Kah-Whye Peng | (Mayo Clinic) |
| Samuel Rabkin | (Harvard Medical School) |
| Stephen Russell | (Mayo Clinic) |
| Leonard Seymour | (University of Oxford) |
| David Stojdl | (Turnstone Biologics) |
| Tomoki Todo | (The University of Tokyo) |
| Chae-Ok Yun | (Hanyang University) |

## Local Organizing Committee

*In alphabetical order, by last name

| | |
|---|---|
| Kazunori Aoki | (National Cancer Center Research Institute) |
| Toshiyoshi Fujiwara | (Okayama University) |
| Hiroshi Fukuhara | (Kyorin University) |
| Norimitsu Kadowaki | (Kagawa University) |
| Chieko Kai | (The University of Tokyo) |
| Hideki Kasuya | (Nagoya University) |
| Kenichiro Kosai | (Kagoshima University) |
| Mikihito Nakamori | (Osaka Minami Medical Center, National Hospital Organization) |
| Takafumi Nakamura | (Tottori University) |
| Toshihiko Okazaki | (Osaka University) |
| Masatoshi Tagawa | (Chiba University) |
| Kenzaburo Tani | (The University of Tokyo) |

## Secretary General

Minoru Tanaka (The University of Tokyo)

## Secretariat of IOVC 2022

c/o Convex Inc.
BPR Place Kamiyacho, 1-11-9 Azabudai, Minato-ku, Tokyo 106-0041 Japan
Tel: +81-3- 3505-1608 Fax: +81-3- 3505-3366
E-mail: iovc2022@convex.co.jp

# Venue Map

## Karuizawa Prince Hotel West





# Reaching People. Touching Lives.
## ― その先に、生きるが実る ―

すべての生命の源である太陽のように、人々にとって、かけがえのない存在でありたい・・・
それが、「サンファーマ」という社名に込められた願いです。
皮膚科学領域のスペシャリティファーマとして、
一人でも多くの患者さんに笑顔をお届けするために、
これからも、私たちは挑戦を続けてまいります。

**サンファーマ株式会社**
東京都品川区西五反田8-9-5

SUN PHARMA

2020年1月作成

# 患者さんとの絆をつなぐ

重篤な疾患と共に生きる患者さんとそのご家族が、笑顔を取り戻し、人生の喜びを感じていただくことがユーシービージャパンの願いです。
私たちは患者さんを全ての中心に据えて、ニューロロジーと免疫・炎症領域に力を注いでいます。
患者さんに鼓舞されて、最先端の科学、革新的な医薬品、実用的なソリューションをさらに一歩進めます。

Inspired by patients.
Driven by science.

**ユーシービージャパン株式会社**

JP-N-OT-2200014

Dermatology
beyond the skin

**We help people achieve healthy skin**

# 私たちは、世界中の人々が健康な肌を手に入れるための手助けをします

レオ ファーマ株式会社は、デンマークに本社を置くLEO Pharma A/S の 100%出資の日本法人として2010年6月に設立されました。
皮膚科領域に特化した、スペシャリティファーマとして日本での確固たる地位を築くべく、事業活動を展開しています。

L E O


## レオ ファーマ株式会社

〒101-0051東京都千代田区神田神保町1-105
神保町三井ビルディング9F
http://www.leo-pharma.jp/


# バイオプシー&
# 極細径インジェクションニードル

MIZUHO
Medical Innovation




■「**①バイオプシー/インジェクションガイド**」に「**②バイオプシープローブ**」を挿入し、バイオプシー後に「**①バイオプシー/インジェクションガイド**」を残したまま「**③インジェクションプローブ**」に差し替えることで、バイオプシーした部位と一致した部位へ的確に薬剤等を投与することが可能です。

■「**③インジェクションプローブ**」の内腔を極細径φ0.3mmに設計。死腔が少なく、目的の薬剤量を投与することが可能です。

■「**②バイオプシープローブ**」と「**③インジェクションプローブ**」は、見分けし易くするため手元のコネクタを異なる形状としました。また「**③インジェクションプローブ**」のコネクタには、投与口が決まった方向にのみ挿入できるよう突起を設けました。

**特許番号：第5665027号　※本製品は、東京大学とのライセンス契約により、実施許諾を受けている特許第5665027号の技術をもとに、弊社が開発した製品です。**

**販売名：バイオプシー/インジェクションニードルキット**
**製造販売承認番号：224ALBZX00031000**


製造業者 ミズホ株式会社 https://www.mizuho.co.jp

【本　　社】〒113-0033 東京都文京区本郷3-30-13
販売事業部／販売マーケティング部／販売技術部 TEL03-3815-3097　特販事業部 TEL03-4334-9111
【営 業 拠 点】北海道 TEL011-716-4731　東　北 TEL022-227-1688　新　潟 TEL025-229-5458　北関東 TEL03-3815-3193
東　海 TEL052-732-7130　関　西 TEL06-6444-3840　中　国 TEL082-241-8826　九　州 TEL092-431-5022
【関東圏販売網（東京都、埼玉県、千葉県、神奈川県）】ミズホアーバン株式会社　〒113-0033　東京都文京区本郷3-29-3　TEL03-3811-0350

ヒト型抗ヒトIL-4/13受容体モノクローナル抗体 薬価基準収載

# デュピクセント® 皮下注 300mg ペン シリンジ

**DUPIXENT®** デュピルマブ(遺伝子組換え)製剤

**生物由来製品、劇薬、処方箋医薬品**(注意-医師等の処方箋により使用すること)

最適使用推進ガイドライン対象品目

効能又は効果、用法及び用量、警告・禁忌を含む注意事項等情報等については電子添文をご参照ください。

sanofi

MAT-JP-2203049-1.0
2022年5月作成

製造販売:サノフィ株式会社
〒163-1488
東京都新宿区西新宿三丁目20番2号

## Registration Desk

The Registration Desk is located at the banquet lobby of Karuizawa Prince Hotel West and is open during the following hours:

| | |
|---|---|
| October 23 (Sunday) | 13:00-18:15 |
| October 24 (Monday) | 07:30-19:15 |
| October 25 (Tuesday) | 08:00-18:00 |
| October 26 (Wednesday) | 08:00-18:00 |

## Registration Fee (For On-site)

| Category | Price |
|---|---|
| Academic | JPY 95,000 |
| Industry | JPY 200,000 |
| Student | JPY 40,000 |
| Accompanying Person (family member) | JPY 30,000 |
| Excursion | JPY 10,000 |

*Welcome Reception, Banquet, and Farewell Dinner are included in registration fee.

## Payment Method

Payment must be made by credit card.
Accepted credit cards are VISA, MasterCard, Diners Club, AMEX, and JCB.

## Name Badge, Certificate and Program Book

You are requested to come to the Registration Desk to pick up your conference kit within the above time frame. The name badge is mandatory for access to all sessions, social events and exhibitions during the conference.

## Abstracts

All abstracts in the program will be available for download from our virtual platform site. Please login with your Registration ID and password to view the abstracts. Please refer to page 15 for the URL and QR code to our virtual platform site.

## Internet Access

Free WiFi is available in the Karuizawa Prince Hotel West at the following places:

- Session Room
- Lounge “KURUMI”
- Lobby

# Conference Information

## PC Preview Desk

The PC Preview Desk is located at "Nagano" lobby of Karuizawa Prince Hotel West and is open during the following hours:

| | |
|---|---|
| October 23 (Sunday) | 15:30-18:15 |
| October 24 (Monday) | 07:30-16:20 |
| October 25 (Tuesday) | 08:00-13:15 |
| October 26 (Wednesday) | 08:00-16:35 |

## Coffee Break

Provided in session room during the following hours:

| | |
|---|---|
| October 24 (Monday) | 09:55-10:25 |
| October 25 (Tuesday) | 09:50-10:10 |
| October 26 (Wednesday) | 10:15-10:45 |

## Lunch/Luncheon Seminar

Lunch boxes will be available at the Session Room during the following hours:

| | |
|---|---|
| October 24 (Monday) | 12:15-13:15 |
| October 25 (Tuesday) | 12:15-13:15 *Luncheon Seminar |
| October 26 (Wednesday) | 12:15-13:15 |

## Afternoon Session

Light snacks and drinks will be provided during the session.

| | |
|---|---|
| October 24 (Monday) Afternoon Session 1 | 15:20-16:20 |
| October 26 (Wednesday) Afternoon Session 2 | 15:05-16:05 |

## Social Events

-Welcome Reception

Date: Sunday, October 23
Time: 18:30-20:30
Place: Chikuma, Karuizawa Prince Hotel West
Fee: Included in the registration fee

-Banquet

Date: Monday, October 24
Time: 19:30-21:30
Place: Asama, Karuizawa Prince Hotel West
Fee: Included in the registration fee
*Entertainment and Japanese cultural performances provided.

-Farewell Dinner

Date: Wednesday, October 26
Time: 19:00-21:00
Place: Asama, Karuizawa Prince Hotel West
Fee: Included in the registration fee
*Entertainment and Japanese cultural performances provided.

-Excursion

Fee: JPY 10,000
Date: Tuesday, October 25
Time: 13:30-17:00
Visiting spots: Onioshidashi Volcanic Park and Shiraito Waterfall
(Schedule is subject to change due to weather conditions)

## Safety and Security

Please do not leave valuable things unattended at any time, whether inside or outside session. We strongly recommend that you use your hotel safety deposit box for your valuables.

## Conference Etiquette

- Participants are advised not to photograph or video and voice recording any sessions without the author's consent. Participants are also advised to obtain consent from authors before citing any of their work presented at the conference.
- Switch your mobile phone to silent mode or turn it off completely during the sessions. Turn off the volume of other electronic devices such as, PC and DVD, and reduce screen brightness. We appreciate your cooperation.

## Prevention Measures against COVID-19

1. If you have a fever or COVID-like symptoms, refrain from attending the conference.
2. Wear your facemask.
3. Hand sanitizers are placed around the conference venue. Clean and disinfect your hands thoroughly.
4. Follow the rules and regulations of the facility.
5. Air ventilation is important in preventing the coronavirus from spreading indoors; due to this, there might be noises and we apologize for the inconvenience.

## Contact

Secretariat of IOVC 2022
c/o Convex Inc.
BPR Place Kamiyacho, 1-11-9 Azabudai, Minato-ku, Tokyo 106-0041 Japan
Tel: +81-3- 3505-1608 Fax: +81-3- 3505-3366
E-mail: iovc2022@convex.co.jp

## Instructions for Presentation On-site

Oral Presentation

1. All presentations will be done on PC.
2. Please bring your own PC or presentation data (PPT). The only PC media that are acceptable are CD-R or USB Flash memory, or your own PC.
3. PCs with Windows 10 and PowerPoint 2013, 2016 are to be used onsite.
   Macintosh users: Please bring your own computer for your presentation.
4. Animation and sound functions will be available. If your presentation data is in PC media, please make sure that the data is compatible with Media Players for Windows. Standard PC fonts for Windows should be used.

## Conference Information

5. If you are using your own PC, please make sure to bring an AC adaptor (standard 2-pin type) to charge your PC. For projector output purposes, a VGA cable or HDMI cable will be provided. Please confirm whether your PC is equipped with a VGA port (mini D-sub 15 pin type) or HDMI port. If you use a different type of port to connect to an external monitor, please bring a converter with you. Please turn off your screen saver and power saving settings in advance, especially if your presentation includes video and sound.



6. Please bring your PC or presentation data to the PC Preview Desk at least 30 minutes prior to your presentation to register and submit it to test the connection and view your file. The PC Preview Desk will be located outside the session room.
7. Please use the mouse on the podium for your presentation. You are required to handle your data yourself, using the mouse connected to the PC.
8. The copied data for your presentation will be deleted by the secretariat after the conference.

Poster Presentation

1. Free discussion
2. At least one author must attend and be available during the poster session on Monday, October 24.
3. Poster board: 90cm wide x 180cm high
4. Presentation number will be provided by the secretariat and will be posted on your assigned board. Your poster can be attached to the board using push pins which will be provided on site.


5. Presenters are requested to follow the schedule below when mounting your poster on the assigned board and removing your poster materials from the board.

Poster set-up and removal schedule:

Set-up: Monday, October 24, 8:00-12:00

Removal: Wednesday, October 26, 16:30-18:00

Note: All posters must be removed during the removal time.

Posters not removed will be discarded by the secretariat.

## Disclosure of Conflicts of Interest (COI)

**Example of declaration in slides**

All presenters must declare their COI status on the first presentation slide (or immediately after the title and presenters) as below.

e.g.1)

IOVC 2022
COI Declaration

Affiliation Name (all presenters)

The presenter has no conflict of interest with any corporate organizations relating to this presentation.

e.g.2)

IOVC 2022
COI Declaration

Affiliation Name (all presenters)

The presenter has conflicts of interest with the corporate organizations below:
Name of organizations

**Disclosure in posters**

Print either "The author has no conflict of interest with any corporate organizations relating to this presentation." or "The author has conflicts of interest with the following corporate organization(s). Names of corporate organization(s)" in an appropriate position (e.g. after the Summary or before or after Acknowledgements).

## Livestreaming & On-demand

To view the livestreaming and on-demand presentations, please access our virtual platform from our website or scan the QR code below. You need to login with your Registration ID and password to view.
All lectures and oral presentations* will be livestreamed and recorded for on-demand viewing. Videos will be available on November 14 (Mon), 2022.
All poster presentation data (pdf) will be posted for on-demand viewing on October 23 (Sun), 2022.
*Note: Certain sessions will not be available on-demand. Please check the program to see which sessions are not included.
Viewing period: October 23 (Sun) – December 31 (Sat), 2022
URL: https://pac-webinar.jp/iovc2022/en/member/login

# Awards

## Golden Virus Award

The Golden Virus Award was established in 2014 as an acknowledgement of the pivotal input that some scientists have had to establishing the field of oncolytic viruses, all the way from the basic concept through to development and licensing of clinical products. The award has taken on huge significance in the field and candidates sometimes spend inestimable efforts in campaigning for the award.

## Travel Awards

The organizing committee will select 10 presenters of the ¥100,000 Travel Award from among the applicants.

**All awardees will be announced during the Farewell Dinner on October 26.**

## Sunday, October 23 — Nagano

### Welcome & Special Lecture

**Chairperson:** Noriyuki Kasahara

16:30-17:15 **SL01: Tomoki Todo**

*The University of Tokyo, Japan*

Clinical development of oncolytic herpes virus in Japan

## Sunday, October 23 — Nagano

### Keynote Lecture 1

**Chairperson:** Evanthia Galanis

17:15-18:15 **INV01: E. Antonio Chiocca**

*Brigham and Women's Hospital, USA*

Oncolytic viruses in clinical trials for brain tumors: a plethora of results in high profile publications

Sponsored by KaliVir Immunotherapeutics, Inc.

## Sunday, October 23 — Chikuma

18:30 Welcome Reception

# Program



## Monday, October 24 — Nagano

### Session 1: Novel Viral Platforms

**Chairpersons:** Brian Lichty, Takafumi Nakamura

**8:30-8:55** — **INV02: Brian D Lichty**
*McMaster University*
Projecting STING Agonism from Oncolytic Viruses

**8:55-9:10** — **INV03: Takafumi Nakamura**
*Division of Molecular Medicine, School of Medicine, Tottori University Faculty of Medicine, Japan*
Next-generation oncolytic vaccinia viral platform

**9:10-9:25** — **INV04: William Jia**
*Virogin Biotech Ltd, Canada*
New Strategies for oncolytic virotherapy: Turning anti-viral immunity to anti-tumor

**9:25-9:40** — **Oral 1: Michael Franti**
*Boehringer Ingelheim, USA*
Path to the clinic: preclinical pharmacokinetics, biodistribution, and immunogenicity strategies to support first-in-man studies with VSV-GP oncolytic virus

**9:40-9:55** — **Oral 2: Xinzhi Zou**
*Stanford University, USA*
Rewiring oncogenic signaling to therapeutic viral activation

Sponsored by Turnstone Biologics

**9:55-10:25** — Coffee Break

## Monday, October 24 — Nagano

### Session 2: Clinical Trials

**Chairpersons:** E. Antonio Chiocca, Toshiyoshi Fujiwara

| | |
|---|---|
| 10:25-10:40 | **INV05: Toshiyoshi Fujiwara**<br>*Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan*<br>Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments |
| 10:40-10:55 | **INV06: Ken-ichiro Kosai**<br>*Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medicine and Dental Sciences, Japan*<br>First-in-human phase I clinical trial of Surv.m-CRA-1 (survivin-responsive conditionally replicating adenovirus) |
| 10:55-11:10 | **Oral 3: James Clubb**<br>*Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland*<br>Ad5/3-E2F-D24-TNFa-IRES-IL2 (TILT-123) from preclinical development to phase I clinical trials |
| 11:10-11:25 | **Oral 4: Hiroshi Nakashima** *No on-demand<br>*Brigham and Women's Hospital and Harvard Medical School, USA*<br>Transcriptome analysis of brain tumor tissues in phase I clinical trial of rQNestin34.5v2 (CAN-311) |
| 11:25-11:40 | **Oral 5: Ulrich M. Lauer**<br>*University Hospital Tuebingen, Germany*<br>Immunovirotherapy as a novel add-on treatment in NUT carcinoma |
| 12:15-13:15 | **Lunch (provided)** |

# Program



## Monday, October 24 — Nagano

### Session 3: Combination Therapies

**Chairpersons:** Shane Foo, Masatoshi Tagawa

**13:30-13:55** — INV07: Shane Foo

*The Institute of Cancer Research, UK*

Oncolytic Maraba Virus primes specific anti-tumour T cell responses in melanoma with therapy dependent on tumour size and enhanced by addition of checkpoint blockade

**13:55-14:10** — INV08: Masatoshi Tagawa

*Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Japan*

An MDM2 inhibitor induces expression of NFI, a cellular factor for adenovirus replications, and augmented cytotoxic effects of adenoviruses through DNA damage pathways

**14:10-14:25** — INV09: Balveen Kaur

*Department of Neurosurgery, University of Texas, USA*

Metabolic strategy to terminate glioblastoma: HSV-P10 reverses Warburg effect and potentiates anti-tumor response in conjunction with CD73 blockade

**14:25-14:40** — INV10: Grant McFadden

*Center for Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, USA*

A novel anti-cancer co-therapy using nuclear export inhibitor Selinexor plus oncolytic Myxoma virus

**14:40-14:55** — Oral 6: Charlotte A Wynn

*Leeds Institute of Medical Research at St. James's, University of Leeds, UK*

Impact of Hepatitis C Virus on Reovirus Immunotherapy for Hepatocellular Carcinoma

**14:55-15:10** — Oral 7: Yasuo Nagai

*Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan*

Combination therapy with telomerase-specific oncolytic adenovirus and PD-L1 blockade against gemcitabine-resistant pancreatic cancer

## Monday, October 24 — Nagano

### Afternoon Session 1

**Chairperson:** Yozo Nakazawa

**15:20-16:20** — INV11: Shinichi Makita *No on-demand

*Department of Hematology, National Cancer Center Hospital, Tokyo, Japan*

CAR T-cell therapy for B-cell non-Hodgkin lymphoma

Sponsored by Daiichi Sankyo Co., Ltd.

**16:20-16:50** — Break

## Monday, October 24 — Nagano

17:00-19:15 Poster Session

## Monday, October 24 — Asama

19:30 Banquet

# Program

## Tuesday, October 25 — Nagano

### Session 4: Novel Viral Platforms

**Chairpersons:** Kah-Whye Peng, Chae-Ok Yun

| | |
|---|---|
| 8:30-8:55 | **INV12: Kah-Whye Peng**<br>*Mayo Clinic, USA*<br>Clinical activity with systemic Voyager-V1 VSV virotherapy in relapsed refractory malignancies |
| 8:55-9:20 | **INV13: Chae-Ok Yun**<br>*Hanyang University, GeneMedicine Co., Ltd., Seoul, Korea*<br>Nanomaterial-based delivery systems to overcome the limitations of oncolytic adenovirus |
| 9:20-9:35 | **INV14: Chieko Kai**<br>*Institute of Industrial Science, The University of Tokyo, Japan*<br>A recombinant measles virus, rMV-SLAMblind is a promising candidate for a novel oncolytic cancer therapy |
| 9:35-9:50 | **Oral 8: Taha Azad**<br>*Ottawa Hospital Research Institute, Ottawa, ON, Canada*<br>Conditionally replicating vaccinia virus platforms As alternatives to Modified Vaccinia Ankara for cancer immunotherapy |
| 9:50-10:10 | Coffee Break |

## Tuesday, October 25 — Nagano

### Session 5: Clinical Trials

**Chairpersons:** Evanthia Galanis, Kenzaburo Tani

**10:10-10:35** — **INV15: Evanthia Galanis**
*Mayo Clinic, USA*
Oncolytic Engineered Measles Virus strains for Glioma Immunovirotherapy

**10:35-10:50** — **INV16: Hiroshi Fukuhara**
*Kyorin University, Japan*
Phase 1 clinical trial of G47Δ in patients with castration-resistant prostate cancer

**10:50-11:05** — **INV17: Toshihiko Okazaki**
*Medical Center for Translational and Clinical Research, Dept. of Medical Innovation, Osaka University Hospital, Osaka, Japan*
Establishing GMP compliant adenovirus serotype-35 manufacturing process development

**11:05-11:20** — **Oral 9: James Burke**
*CG Oncology, USA*
CG0070 for the treatment of non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)

**11:20-11:35** — **Oral 10: Frank Tufaro**
*VCN Biosciences- Synthetic Biologics, Spain*
VCN-01 changes tumor stroma when administered systemically in combination with Durvalumab (MEDI4736) in subjects with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): Biological data of a Phase I Study

**11:35-11:50** — **Oral 11: Shruthi Naik**
*Mayo Clinic Department of Molecular Medicine, USA*
Intravesical oncolytic measles virus therapy for bladder cancer

**11:50-12:05** — **Oral 12: Siddhartha Yadav**
*Department of Oncology, Mayo Clinic, Rochester, MN, USA*
A first-in-human phase I clinical trial of intratumor administration of a measles virus derivative expressing the Helicobacter pylori neutrophil-activating protein in patients with metastatic breast cancer

# Program

## Tuesday, October 25 — Nagano

### Luncheon Seminar

**Chairperson:** Norimitsu Kadowaki

12:15-13:15 **INV18: Masahiro Abe** *No on-demand

*Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School, Tokushima, Japan*

Pathogenesis of bone destruction and tumor progression in multiple myeloma: the role of RANKL

Sponsored by Daiichi Sankyo Co., Ltd.



## Tuesday, October 25

13:30-17:00 Excursion

## Tuesday, October 25

### 日本ウイルス療法学会発足記念講演
### Inaugural Lecture for the establishment of the Japan Society of Oncolytic Virus Therapy

**Chairperson:** Tomoki Todo

17:45-18:45 **Hiroyuki Mano**

*Director, Research Institute/Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center*

がん研究が拓く未来の医療

Precision medicine driven by cancer research

## Wednesday, October 26 — Nagano

### Session 6: Payloads and Mechanisms of Action

**Chairpersons:** Grant McFadden, Kazunori Aoki

| | |
|---|---|
| 8:30-8:45 | **INV19: Kazunori Aoki**<br>*National Cancer Center Research Institute, Japan*<br>Development of Oncolytic Adenoviruses Targeting Advanced Pancreatic Carcinoma |
| 8:45-9:00 | **Oral 13: Steve H Thorne**<br>*Kalivir Immunotherapuetics, USA*<br>A novel oncolytic virotherapy, VET3-TGI, displays potent therapeutic activity in multiple mouse tumor models through blocking TGF-beta and augmenting type-1 immune response |
| 9:00-9:15 | **Oral 14: Ugo Hirigoyen**<br>*INSERM Nantes University, France*<br>Characterization of tumor extracellular vesicles produced during oncolytic infection |
| 9:15-9:30 | **Oral 15: Michael C Brown**<br>*Duke University Medical School, Durham, NC, USA*<br>Intratumor polio vaccine-specific CD4+ T cell recall coordinates antitumor type I and II immunity during polio virotherapy |
| 9:30-9:45 | **Oral 16: Louisa S Chard Dunmall**<br>*Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UK*<br>Intravenous delivery of Vaccinia virus expressing interleukin-21 in combination with immune checkpoint inhibition is an effective treatment for glioblastoma |
| 9:45-10:00 | **Oral 17: Jianhua Yu**<br>*Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.*<br>Specific targeting of glioblastoma with an oncolytic virus expressing a Cetuximab-CCL5 fusion protein induces both innate and adaptive anti-tumor immunity |
| 10:00-10:15 | **Oral 18: Tacien Petithomme**<br>*CRCI2NA, Inserm, LabEx IGO, Nantes University, France*<br>Novel chimeric proteins as immunoactivating transgenes for oncolytic immunotherapy |
| 10:15-10:45 | **Coffee Break** |

# Program

## Wednesday, October 26 — Nagano

### Keynote Lecture 2

**Chairperson:** Kerry Fisher

10:45-11:45 **INV20: Marta M Alonso**
*Dpt. Of Pediatrics, Navarra University Clinic, Pamplona, Spain*
Translating the Delta-24 Oncolytic Adenovirus Platform for Pediatric Brain Tumors

Sponsored by Replimune

12:15-13:15 **Lunch (provided)**

## Wednesday, October 26 — Nagano

### Session 7: Combination Therapies

**Chairpersons:** Kerry Fisher, Norimitsu Kadowaki

13:30-13:55 **INV21: Kerry Fisher**
*University of Oxford, UK*
Targeting tumour stroma with oncolytic viruses

13:55-14:10 **INV22: Norimitsu Kadowaki**
*Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa*
Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms

14:10-14:25 **INV23: Mikihito Nakamori**
*Division of Digestive Surgery, Osaka Minami Medical Center, National Hospital Organization*
Therapeutic development of oncolytic herpes viruses for advanced gastric cancer

14:25-14:40 **Oral 19: Richard Baugh**
*University of Oxford, UK*
Targeting stress-associated ligands in glioblastoma with a bispecific T cell engager synergises with conventional therapy and enhances oncolytic virotherapy

14:40-14:55 **Oral 20: Candelaria Gomez-Manzano**
*MD Anderson Cancer Center, Houston, TX, USA*
Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD

## Wednesday, October 26 — Nagano

### Afternoon Session 2

**Chairperson:** Kenzaburo Tani

15:05-16:05 **INV24: Makoto Yamagishi** *No on-demand

*Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan*

Overall Picture of Genetic and Epigenetic Characteristics in HTLV-1-Associated Diseases

Sponsored by Daiichi Sankyo Co., Ltd.

16:05-16:35 Break

## Wednesday, October 26 — Nagano

### Session 8: Novel Viral Platforms

**Chairpersons:** Noriyuki Kasahara, Hideki Kasuya

16:35-17:00 **INV25: Noriyuki Kasahara**

*University of California San Francisco, USA*

17:00-17:15 **INV26: Hideki Kasuya**

*Nagoya University, Japan*

The novel armed oncolytic HSV exhibits a strong antitumor effect that completely regresses tumors

17:15-17:30 **INV27: Kenzaburo Tani**

*Laboratory of ALA-Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Japan*

Preclinical studies of Coxackieviruses as new oncolytic virus

17:30-17:45 **Oral 21: Eriko Matsuda**

*Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Japan*

Development of a method using oncolytic adenovirus to specifically eliminate tumorigenic cells in pluripotent stem cell-based regenerative medicine

17:45-18:00 **Oral 22: Ahmet Hazini**

*Department of Oncology, University of Oxford, UK*

Promoting improved agnostic cross presentation of tumour antigens with an oncolytic adenovirus expressing RIPR-SIRPa

## Wednesday, October 26 — Asama

19:00-21:00 Farewell Dinner

# Sponsors & Exhibitors

## International Sponsors

### Diamond Level

#### KaliVir Immunotherapeutics, Inc.

KaliVir Immunotherapeutics is a pioneering and science-driven biotechnology company dedicated to developing cutting-edge, next-generation oncolytic viral immunotherapy for treatment of cancer. We harness the unique biology of the vaccinia virus to create optimized, enhanced oncolytic viral backbones for building novel oncolytic vaccinia candidates. Our proprietary Vaccinia Enhanced Template (VETTM) platform employs multiple proprietary genetic modifications that can be combined to generate unique oncolytic vaccinia viruses that are optimized for systemic delivery and expression of therapeutic transgenes within target tumors. We continue to expand our product pipeline using the VETTM platform, and are now advancing multiple therapeutic candidates toward the clinic. KaliVir is located in Pittsburgh, Pennsylvania. For more information, visit www.kalivir.com.

### Platinum Level

#### Replimune Inc.

Replimune is pioneering a new class of tumor directed oncolytic immunotherapies (TDOI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company's approach is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but to also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination. The approach is expected to be highly synergistic with immune checkpoint blockade and other methods of treatment across a broad range of cancers. With deep experience across drug development and commercialization, the Replimune team is now focused on delivering therapies to patients that are intended to be significant improvements compared to what was previously possible, and which will broaden the use of OI well beyond immune responsive cancers to the full range of solid tumor types. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma – and will be the basis for establishing a broad skin cancer franchise. Two further product candidates, RP2 and RP3, are currently in Phase 1/2 clinical development. Replimune has completed buildout of its 63,000-square-foot state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products.

### Gold Level

#### Turnstone Biologics

Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering differentiated approaches with two clinically validated technologies, tumor infiltrating lymphocyte (TIL) therapy and viral immunotherapy. Turnstone's innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the Company's foundational therapeutic modality driving its cancer immunotherapy pipeline. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

### Silver Level

#### GeneMedicine Co., Ltd

GeneMedicine Co., Ltd. is a research-based biotechnology company focused on developing and commercializing tumor-targeted and systemically deliverable oncolytic adenovirus for the treatment of intractable cancers. These state-of-the-art technologies are the achievement of 25 years of extensive and rigorous R&D. Since the establishment in 2014, GeneMedicine has reached two licensing-out agreements with two U.S. biotech companies. GeneMedicine possess systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system and various blood components. It definitely differentiates GeneMedicine from any other competitors in the global oncolytic virus therapy market. GeneMedicine has already successfully completed phase I clinical trial of GM101 with excellent safety and efficacy profile, and on the way to start phase II clinical trial soon. Recently, the company has submitted global IND documents to KFDA and US FDA to begin clinical trial of GM103 pipeline against recurrent solid tumor patients. GeneMedicine has also launched a CDMO services specializing in production of viral vectors, such as Ad, AAV, lentivirus, HSV and etc., for clients around the world to facilitate transition of innovative gene therapeutics into clinical trials.

## Bronze Level

### CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing urologic oncology agents that improve patient bladder preservation, quality of life, and life span. Our lead candidate, CG0070, is an oncolytic immunotherapy based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene. CG0070 replicates and expresses therapeutic payload in cancer cells with a defective retinoblastoma (Rb) pathway. Early clinical investigations have established monotherapy activity in BCG-unresponsive NMIBC following intravesical delivery. The current, active CGO clinical program includes studies of CG0070 alone and in combination with check point inhibitor therapy. Monotherapy CG0070 is being assessed in a Phase 3, registration directed trial for the treatment of BCG-unresponsive NMIBC (Non-Muscle Invasive Bladder Cancer) and in a Phase 1b study of intermediate risk bladder cancer. Phase 2 combination studies exploring CG0070 with pembrolizumab for the treatment of BCG-unresponsive NMIBC and with nivolumab targeting muscle invasive disease, are ongoing.
To learn more please visit: www.cgoncology.com.

## Exhibitors

### ArcticZymes Techonologies ASA

ArcticZymes Technologies ASA is born from the unique conditions in the Arctic and our innovations in Tromsø (Norway) where we have been developing and manufacturing cold-adapted enzymes for more than 30 years. We are a specialized manufacturer of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD), and biomanufacturing.
In biotherapeutics such as oncolytic virus therapy, gene therapy and vaccine production our enzymes are tailor-made for optimal performance in multiple bioprocessing and biomanufacturing workflows.
Beyond the unique features, ArcticZymes Technologies is committed to providing premium and highest quality enzymes, with emphasis on robust manufacturing and reliability of supply. Our no-compromises approach to become a long-term partner with our customers has enabled countless innovations and products to successfully reach the market. Furthermore, our enzymes targeted for biotherapeutic use are specially developed to suit high quality measurements and regulatory requirements simplifying their use in GMP compliant processes.
ArcticZymes Technologies is trusted by leading molecular research kit manufacturers, diagnostic assay developers, and biotherapeutic and biomanufacturing companies around the world.
We provide enzymes technologies and support adapted to your needs. To find out more, please visit: www.arctizymes.com

### Daiichi Sankyo Company, Limited

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

# Sponsors & Exhibitors

## List of Sponsors

*In alphabetical order

ArcticZymes Technologies ASA
Astellas Pharma Inc.
CG Oncology
Daiichi Sankyo Company, Limited
Denka Company Limited
GeneMedicine Co., Ltd
Iwai Chemicals Company
KaliVir Immunotherapeutics, Inc
LEO Pharma K.K.
Maruho Co., Ltd.
Minophagen Pharmaceutical Co., Ltd.
MIZUHO Corporation
Nacalai Tesque, Inc.
Nippon Boehringer Ingelheim Co ., Ltd.
Novartis Pharma K.K.
Replimune
Sanofi K.K.
Sun Pharma Japan Limited
Turnstone Biologics
UCB Japan Co. Ltd.

As of October 12, 2022


Replimune is pioneering a new class of tumor directed oncolytic immunotherapies (TDOI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company's approach is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but to also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination. The approach is expected to be highly synergistic with immune checkpoint blockade and other methods of treatment across a broad range of cancers. With deep experience across drug development and commercialization, the Replimune team is now focused on delivering therapies to patients that are intended to be significant improvements compared to what was previously possible, and which will broaden the use of OI well beyond immune responsive cancers to the full range of solid tumor types. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma – and will be the basis for establishing a broad skin cancer franchise. Two further product candidates, RP2 and RP3, are currently in Phase 1/2 clinical development. Replimune has completed buildout of its 63,000-square-foot state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products.

病気になる。あるいは、健康への心配がある。
それだけで、人は日常から引き離されてしまう。
第一三共が掲げる「健康で豊かな生活」とはつまり、
すべての人が前向きに日々を生きられる、ということ。
わたしたちがサイエンス＆テクノロジーで、
革新的モダリティ（治療手段）を追求するのも、そのためです。
健康につまずかない。そんなサステナブルな未来へ。
わたしたちは今日も、イノベーションの先にあるこたえをさがしています。

## 世界中の人々の健康で豊かな生活に貢献する

イノベーションに情熱を。
ひとに思いやりを。

Daiichi-Sankyo
第一三共株式会社

# Multiple Therapies, One Virus

Breakthrough Oncolytic Vaccinia Virus Immunotherapy Platform

KALIVIR is dedicated to developing systemically deliverable next-generation oncolytic virus immunotherapies. We have designed a new class of oncolytic virus that combines the natural ability of viruses to kill cancers with novel mechanisms to stimulate anti-tumor immunity and modulate the tumor microenvironment to maximize targeted tumor killing. Our oncolytic product candidates are designed to be safe, potent and systemically deliverable across different tumor types. We are now advancing multiple therapeutic candidates toward the clinic.

KALIVIR has developed a novel, potent oncolytic platform called the Vaccinia Enhanced Template (VET™). Our VET™ Platform includes multiple proprietary genetic modifications that can be combined to generate unique oncolytic viruses optimized for systemic delivery and expression of therapeutic transgenes within target tumors.

Our proprietary VET™ modifications enhance vaccinia virus' systemic delivery capabilities, tumor-targeted replication, and spread within and between tumors.

KALIVIR's VET™ Platform is a versatile viral backbone that can be harnessed to create novel, best-in-class oncolytic immunotherapies.

Using the VET™ Platform, we design and construct oncolytic candidates through rigorous testing and scientific evaluation to tailor each virus for the payload and the target tumor. Genetic modifications derived from the VET™ Platform operate synergistically, rather than piecewise, to enable the most effective tumor killing and immune modulation.

We have partnered with Astellas and Roche to develop novel oncolytic vaccinia candidates using the VET™ Platform.

To learn more about us, please visit www.kalivir.com

## VET™ | Vaccinia Enhanced Template




**Enhanced IV Delivery:**
*in situ* cell-based targeted delivery via chemokine receptor expression

**Enhanced Tumor-selective Replication:**
Modifications to increase replication selectively in cancer cells

**Enhanced Spread:**
Modifications to degrade extracellular matrix for increased viral spread in the tumor and spread to metastases

**Enhanced Viral Immune Avoidance:**
Re-targeting of immune response towards tumor by concealing viral antigens from the immune response